OnPoint Vision Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$11M
- Investors
-
2
OnPoint Vision General Information
Description
Developer of an intraocular pseudophakic contact lens designed to treat refractive errors and low vision. The company provides intraocular lenses that correct the residual refractive error in patients who have already undergone cataract surgery, as well as employs in the treatment of visual decline due to age-related retinal pathologies, enabling patients to have access to surgical tools.
Contact Information
Website
www.onpoint-vision.comCorporate Office
- 6A Liberty Street
- Suite 100
- Aliso Viejo, CA 92626
- United States
Corporate Office
- 6A Liberty Street
- Suite 100
- Aliso Viejo, CA 92626
- United States
OnPoint Vision Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series B) | 11-Dec-2023 | $11M | Completed | Generating Revenue |
OnPoint Vision Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 1,500,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 22.24% |
OnPoint Vision Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OnPoint Vision Patents
OnPoint Vision Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250213389-A1 | Ocular drug delivery devices securely implantable into anterior segment of eye | Pending | 02-Jan-2024 | ||
| AU-2021315853-A1 | Intraocular pseudophakic contact lens (iopcl)-based telescopic approach for treating age-related macular degeneration (amd) or other eye disorders | Active | 28-Jul-2020 | ||
| AU-2021315853-B2 | Intraocular pseudophakic contact lens (iopcl)-based telescopic approach for treating age-related macular degeneration (amd) or other eye disorders | Active | 28-Jul-2020 | ||
| CA-3177409-A1 | Intraocular pseudophakic contact lens (iopcl)-based telescopic approach for treating age-related macular degeneration (amd) or other eye disorders | Pending | 28-Jul-2020 | ||
| EP-4132422-A1 | Intraocular pseudophakic contact lens (iopcl)-based telescopic approach for treating age-related macular degeneration (amd) or other eye disorders | Pending | 28-Jul-2020 | A61F2/1651 |
OnPoint Vision Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
OnPoint Vision Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| VisAbility Micro-Insert System | Corporation | Minority | ||
| WP Global Partners | PE/Buyout | Minority |
OnPoint Vision FAQs
-
When was OnPoint Vision founded?
OnPoint Vision was founded in 2019.
-
Where is OnPoint Vision headquartered?
OnPoint Vision is headquartered in Aliso Viejo, CA.
-
What is the size of OnPoint Vision?
OnPoint Vision has 20 total employees.
-
What industry is OnPoint Vision in?
OnPoint Vision’s primary industry is Therapeutic Devices.
-
Is OnPoint Vision a private or public company?
OnPoint Vision is a Private company.
-
What is the current valuation of OnPoint Vision?
The current valuation of OnPoint Vision is .
-
What is OnPoint Vision’s current revenue?
The current revenue for OnPoint Vision is .
-
How much funding has OnPoint Vision raised over time?
OnPoint Vision has raised $11M.
-
Who are OnPoint Vision’s investors?
VisAbility Micro-Insert System and WP Global Partners have invested in OnPoint Vision.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
